RxDoctor Payments Data

Julian McQuirter, MD

Internal Medicine · Fort Lauderdale, FLNPI 1396719449

Payments from drug & device makers

$7,314in general payments, 2019–2025

Across 389 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$830
  • Johnson & Johnson$806
  • AbbVie$717
  • Novo Nordisk$554
  • Pfizer$489
  • AstraZeneca$439
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,300100%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,314 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$27,769
Medicare patients
85
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$108,349
FarxigaDapagliflozin Propanediol52$55,126
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$55,015
JardianceEmpagliflozin35$48,528
EliquisApixaban45$39,436
XareltoRivaroxaban46$38,459
RybelsusSemaglutide21$32,430
DescovyEmtricitabine/Tenofov Alafenam15$32,295
EntrestoSacubitril/Valsartan27$30,389
TradjentaLinagliptin14$13,476
LinzessLinaclotide13$10,885
VascepaIcosapent Ethyl12$9,426
Albuterol Sulfate HfaAlbuterol Sulfate188$8,951
SymbicortBudesonide/Formoterol Fumarate14$8,099
MovantikNaloxegol Oxalate13$5,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$554$140,778117 claims
AstraZenecaFarxiga, Symbicort$439$63,22566 claims
Boehringer IngelheimJardiance, Tradjenta$146$62,00349 claims
GSKTrelegy Ellipta$217$55,01547 claims
PfizerEliquis, Paxlovid$489$43,39857 claims
Johnson & JohnsonXarelto$806$38,45946 claims
GileadDescovy$260$32,29515 claims
NovartisEntresto$97$30,38927 claims
AbbVieLinzess, Synthroid$717$12,82827 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$391$4,49311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →